Soligenix Inc. Targets Key Milestones in Rare Disease Pipeline with Potential $2 Billion Global Opportunity
Soligenix Inc. outlines significant clinical and strategic milestones for its rare disease therapies, including Phase 3 FLASH 2 results for HyBryte(TM) and updates on psoriasis and Behçet’s Disease treatments, projecting over $90 million in U.S. annual sales and global opportunities exceeding $2 billion.
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has announced a series of upcoming clinical and strategic milestones that could significantly impact its pipeline and financial outlook. The company's President and CEO, Dr. Christopher J. Schaber, highlighted key developments, including the anticipated Phase 3 FLASH 2 results for HyBryte(TM) in treating cutaneous T-cell lymphoma, expected in the second half of 2026. Additionally, updates on treatments for psoriasis (SGX302) and Behçet’s Disease (SGX945) are slated for the third and fourth quarters of 2025.
An investigator-initiated study has already demonstrated promising results, with a 75% success rate at 18 weeks. Soligenix projects that HyBryte(TM) could achieve peak U.S. annual sales of over $90 million, with global opportunities across its pipeline exceeding $2 billion. The company, which currently holds approximately $7 million in cash, is actively exploring partnerships and mergers and acquisitions to extend its cash runway into the first quarter of 2026. This strategic planning is aimed at preparing for global regulatory filings and the potential commercialization of its therapies.
For more information on Soligenix's developments, visit https://www.Soligenix.com.